BALAXI vs FISCHER: Stock Comparison
FISCHER MEDICAL VENTURE L is the larger company by market capitalisation. BALAXI PHARMA shows a lower P/E, a higher ROE and a higher ROCE, while FISCHER MEDICAL VENTURE L shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALAXI leads 5; FISCHER leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALAXI | FISCHER |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Medical Equipment & Supplies |
Price
| Metric | BALAXI | FISCHER |
|---|---|---|
| Live Price | ₹23.12 | ₹32.95 |
| Day Change | -1.24% | 0.24% |
| Volume | 22,486 | 74.83 L |
| 52-Week High | ₹47.71 | ₹124.7 |
| 52-Week Low | ₹15.2 | ₹31.05 |
| Distance from 52W High | -51.54% | -73.58% |
Valuation
| Metric | BALAXI | FISCHER |
|---|---|---|
| Market Cap | ₹127 Cr | ₹2,200 Cr |
| P/E Ratio | 12.63x | 71.74x |
| P/B Ratio | 0x | 5.62x |
| EPS | ₹0.45 | ₹0.45 |
| Book Value | ₹45.12 | ₹5.96 |
| Dividend Yield | 0% | 0.15% |
Growth
| Metric | BALAXI | FISCHER |
|---|---|---|
| Revenue Growth (TTM YoY) | -25.76% | 98.7% |
| EPS Growth (TTM YoY) | -58.44% | 0% |
| Qtr Sales Growth | -80.68% | 11,250.98% |
| Qtr Profit Growth | -196.59% | 208.2% |
Profitability & Leverage
| Metric | BALAXI | FISCHER |
|---|---|---|
| ROE | 3.87% | -3.08% |
| ROCE | 4.42% | -1.67% |
| Net Margin | 0.52% | 6.79% |
| Operating Margin | 12.03% | -33.66% |
| Debt to Equity | 0.25x | 0.04x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BALAXI | FISCHER |
|---|---|---|
| Promoter Holding | 65.99% | 12.31%▲ 0.85 pp |
| FII Holding | 0% | 5.57%▲ 0.09 pp |
| DII Holding | 2.56% | 1.26%▼ 0.09 pp |
| Public Holding | 31.45% | 30.09%▼ 0.93 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALAXI PHARMA and FISCHER MEDICAL VENTURE L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.